A
Andreas Harstrick
Researcher at Merck KGaA
Publications - 9
Citations - 4831
Andreas Harstrick is an academic researcher from Merck KGaA. The author has contributed to research in topics: Cancer & DARPin. The author has an hindex of 4, co-authored 8 publications receiving 4666 citations.
Papers
More filters
Journal ArticleDOI
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham,Yves Humblet,Salvatore Siena,David Khayat,Harry Bleiberg,Armando Santoro,D. Bets,M. Mueser,Andreas Harstrick,Chris Verslype,Ian Chau,Eric Van Cutsem +11 more
TL;DR: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Journal ArticleDOI
Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Jean Bourhis,Fernando Rivera,Ricard Mesia,Ahmad Awada,Lionel Geoffrois,Christian Borel,Yves Humblet,Antonio Lopez-Pousa,Ricardo Hitt,M. Eugenia Vega Villegas,Lionel Duck,Dominique Rosine,Nadia Amellal,Armin Schueler,Andreas Harstrick +14 more
TL;DR: The combination of cetuximab, cisplatin/carboplatin, and FU was reasonably well tolerated and active in recurrent/metastatic SCCHN, and merits additional investigation.
Journal ArticleDOI
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Richard D. Baird,Constanza Linossi,Mark R. Middleton,Simon Lord,Adrian L. Harris,Jordi Rodon,Jordi Rodon,Christof Zitt,Ulrike Fiedler,Keith M. Dawson,Nicolas Leupin,Michael T. Stumpp,Andreas Harstrick,Analia Azaro,Stefanie Fischer,Aurelius Omlin +15 more
TL;DR: MP0250 is a first-in-class DARPin drug candidate with suitable tolerability and appropriate pharmacokinetic properties for further development in combination with other anticancer therapies.
Proceedings ArticleDOI
Abstract OT1-03-02: MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors
Richard D. Baird,Aurelius Omlin,J Kiemle-Kallee,Ulrike Fiedler,Christof Zitt,D. Feurstein,J Herbst,Keith M. Dawson,E vom Baur,Michael T. Stumpp,Frank Hermann,Andreas Harstrick,A Schneeweiss +12 more
TL;DR: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors, suggesting it could be a valid treatment option for HER2 positive cancers.
Proceedings ArticleDOI
Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors
Jordi Rodon,Aurelius Omlin,Karin H. Herbschleb,Javier Garcia-Corbacho,Jan Steiner,Ignacio Dolado,Christof Zitt,Daniel Feurstein,Dascha Turner,Keith M. Dawson,Michael T. Stumpp,Patrick Gilboy,Andreas Harstrick,Analia Azaro,Christoph Jakob Ackermann,Mark R. Middleton,Richard D. Baird +16 more
TL;DR: Rodon et al. as mentioned in this paper proposed a tri-specific DARPin with the ability to simultaneously neutralize the activities of VEGF and HGF and also to bind to human serum albumin (HSA) to give an increased plasma half-life and potentially enhanced tumor penetration.